BB Biotech AG reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was CHF 0.1 million compared to CHF 220.99 million a year ago. Net loss was CHF 48.39 million compared to net income of CHF 210.28 million a year ago. Basic loss per share from continuing operations was CHF 0.89 compared to basic earnings per share from continuing operations of CHF 3.83 a year ago. Diluted loss per share from continuing operations was CHF 0.89 compared to diluted earnings per share from continuing operations of CHF 3.83 a year ago.
For the nine months, revenue was CHF 0.622 million compared to CHF 1.26 million a year ago. Net loss was CHF 315.72 million compared to CHF 322.65 million a year ago. Basic loss per share from continuing operations was CHF 5.76 compared to CHF 5.86 a year ago. Diluted loss per share from continuing operations was CHF 5.76 compared to CHF 5.86 a year ago.